.Attribute Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a typical consequence of 11 months, people along with metastatic gastrointestinal lumps that received biomarker-matched treatments based upon circulating cyst DNA profiling presented a greater professional advantage than those acquiring unmatched treatment.